Levin Capital Strategies L.P. Buys 168,201 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

Levin Capital Strategies L.P. grew its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) by 56.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 467,627 shares of the company’s stock after buying an additional 168,201 shares during the period. Levin Capital Strategies L.P. owned 0.48% of ARS Pharmaceuticals worth $4,933,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Rhumbline Advisers raised its position in shares of ARS Pharmaceuticals by 2.9% during the fourth quarter. Rhumbline Advisers now owns 65,163 shares of the company’s stock valued at $687,000 after buying an additional 1,824 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in ARS Pharmaceuticals by 10.5% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 20,607 shares of the company’s stock worth $217,000 after purchasing an additional 1,962 shares during the last quarter. Creative Planning increased its position in ARS Pharmaceuticals by 7.0% in the third quarter. Creative Planning now owns 35,263 shares of the company’s stock worth $511,000 after purchasing an additional 2,307 shares during the last quarter. HighTower Advisors LLC increased its position in ARS Pharmaceuticals by 18.2% in the third quarter. HighTower Advisors LLC now owns 28,310 shares of the company’s stock worth $411,000 after purchasing an additional 4,369 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC increased its position in ARS Pharmaceuticals by 9.1% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 57,624 shares of the company’s stock worth $836,000 after purchasing an additional 4,810 shares during the last quarter. Institutional investors own 68.16% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently weighed in on SPRY. William Blair restated an “outperform” rating on shares of ARS Pharmaceuticals in a research report on Friday, February 21st. Leerink Partners boosted their price target on shares of ARS Pharmaceuticals from $26.00 to $27.00 and gave the stock an “outperform” rating in a research report on Monday, January 13th. Raymond James boosted their price target on shares of ARS Pharmaceuticals from $26.00 to $28.00 and gave the stock a “strong-buy” rating in a research report on Tuesday, January 14th. Finally, Oppenheimer began coverage on shares of ARS Pharmaceuticals in a research report on Monday, February 10th. They issued an “outperform” rating and a $40.00 price target on the stock. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $28.80.

Insider Buying and Selling at ARS Pharmaceuticals

In other news, insider Sarina Tanimoto sold 100,000 shares of the business’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $13.16, for a total transaction of $1,316,000.00. Following the completion of the sale, the insider now directly owns 1,148,499 shares of the company’s stock, valued at approximately $15,114,246.84. The trade was a 8.01 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Justin Chakma sold 45,000 shares of the business’s stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $13.19, for a total transaction of $593,550.00. Following the sale, the insider now directly owns 136,380 shares of the company’s stock, valued at $1,798,852.20. This represents a 24.81 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 559,288 shares of company stock worth $7,116,694 over the last quarter. Insiders own 40.10% of the company’s stock.

ARS Pharmaceuticals Stock Up 2.7 %

SPRY stock opened at $10.48 on Friday. ARS Pharmaceuticals, Inc. has a twelve month low of $7.55 and a twelve month high of $18.51. The stock has a market capitalization of $1.02 billion, a price-to-earnings ratio of -20.55 and a beta of 0.99. The firm’s fifty day simple moving average is $11.93 and its two-hundred day simple moving average is $13.23.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.